A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT00721331
• Recruitment Status: Completed
• First Posted: July 24, 2008
• Last Update Posted: September 26, 2008
• Sponsor: Zalicus
• Information provided by: Zalicus

Study Description

Brief Summary:

This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free vehicle cream of CRx-197)in healthy volunteers.

Condition or disease	Intervention/treatment	Phase
Atopic Dermatitis	Drug: nortriptyline HCl + loratadine; Drug: nortriptyline HCl; Drug: mometasone furoate; Drug: Active ingredient free vehicle cream of CRx-197	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
• Study Start Date: July 2008
• Actual Primary Completion Date: September 2008
• Actual Study Completion Date: September 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)	Drug: nortriptyline HCl + loratadine; Topical
Experimental: CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)	Drug: nortriptyline HCl + loratadine; Topical
Experimental: 0.1% nortriptyline HCl	Drug: nortriptyline HCl; Topical
Active Comparator: 0.1% mometasone furoate	Drug: mometasone furoate; Topical
Placebo Comparator: Active ingredient free vehicle cream of CRx-197	Drug: Active ingredient free vehicle cream of CRx-197; Topical

Outcome Measures

Primary Outcome Measures :

1. Safety and tolerability of CRx-197 as assessed by treatment emergent adverse events, physical exams, vital signs, concomitant medications/procedures and subject assessment of pruritus. [ Time Frame: 2 months ]

Secondary Outcome Measures :

1. Difference in change from baseline in psoriatic infiltrate measured by ultrasound between CRx-197, nortriptyline, active comparator as well as vehicle of CRx-197 and untreated test field(s) [ Time Frame: Days 8, 15, 22, 29 and 43 ]
2. Difference in change from baseline in erythema measured by chronometry between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) and normal skin [ Time Frame: Days 8, 15, 22, 29 and 43 ]
3. Modified PASI between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) [ Time Frame: Baseline, and Days 8, 15, 22, 29 and 43 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Subject must voluntarily sign and date the written Informed Consent prior to any study specific procedures
• Subject must be 18 to 60 years of age
• Subject must have healthy skin on which reddening can be easily recognized in the area where they will place the test fields
• Subject must be free from a condition/disease that the investigator feels interferes with the interpretation of the study results.
• Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen. A highly effective method of birth control is defined as those which result in a lower failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner.

Exclusion Criteria:

• Suntan, hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields
• Dark skinned persons whose skin color prevents ready assessment of skin reactions
• Cardiac disease, including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias and valvular heart disease
• Mania
• Narrow angle glaucoma
• Hyperthyroidism by medical history, TSH less than LLN, or subject receiving any thyroid medication
• Severe liver disease - ALT laboratory value that exceeds 1.5x ULN
• Inflammatory dermatoses (e.g., atopic dermatoses/eczema, psoriasis)
• Any skin condition involving the test fields including but not limited to bacterial, viral, or fungal skin infections, acne, rosacea
• Active varicella, tuberculosis, syphilis or post-vaccine reactions
• Autoimmune disease (e.g., lupus erythematosis)
• Known allergic reactions or hypersensitivity to any of the components of the study treatments
• Allergy to adhesives on the patches used for occlusion in the study
• UV therapy or significant UV exposure in the four weeks before treatment application
• History of malignancy (except for treated or excised basal cell carcinoma)
• Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
• History of drug or alcohol abuse (as defined by the Investigator)
• Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study
• Positive for HIV antibody
• Systemic treatments in the four weeks prior to treatment application that may interact with any of the study drugs, such as: Glucocorticoids, MAO inhibitors, anti-depressants, anti-seizure medications, anti-psychotics and anti-histamines
• Subjects who require medications that inhibit the CYP450 2D6 pathway such as:Quinidine, Cimetidine, Type 1 anti-arrhythmic, Phenothiazines, Selective serotonin reuptake inhibitors, Reserpine, other anticholinergic drugs, and sympathomimetic drugs
• Treatment with any investigational agent within one month before treatment application for this trial
• Female subject who is pregnant , lactating, or with a positive pregnancy test
• Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule
• Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment
• Subject is institutionalized because of legal or regulatory order

Contacts and Locations

Locations

Germany

PROINNOVERA GmbH

Muenster, Germany

Sponsors and Collaborators

Zalicus

Investigators

• Principal Investigator: Jutta Harten, MD; Proinnovera GmbH

More Information

• Responsible Party: James Keane, Sr. Clinical Project Manager, CombinatoRx, Inc.
• ClinicalTrials.gov Identifier: NCT00721331
• Other Study ID Numbers: CRx-197-001; EudraCT # 2008-000611-15
• First Posted: July 24, 2008
• Last Update Posted: September 26, 2008
• Last Verified: September 2008

Keywords provided by Zalicus:

CombinatoRx; Atopic; Dermatitis; Topical; CRx-197; Normal Healthy Volunteers

Additional relevant MeSH terms:

Dermatitis, Atopic; Dermatitis; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Mometasone Furoate; Loratadine; Nortriptyline; Anti-Inflammatory Agents; Dermatologic Agents; Anti-Allergic Agents; Antipruritics; Histamine H1 Antagonists, Non-Sedating; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Antidepressive Agents, Tricyclic; Antidepressive Agents; Psychotropic Drugs; Adrenergic Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Adrenergic Agents